Alithea Genomics, a Lausanne, Switzerland-based leader in the field of RNA sequencing and transcriptomics analysis, raised CHF1M in Seed funding.
The round was led by Novalis Biotech Acceleration fund with participation of Swiss-based private investors. Jan Van den Berghe, co-founder and managing director of Novalis Biotech, has been appointed to the board of directors.
The company intends to use the funds to expand the commercialization and scale-up of its new products, MERCURIUS™ BRB-seq and MERCURIUS™ Blood BRB-seq.
Led by CEO Riccardo Dainese, Alithea Genomics has developed proprietary technology called Bulk RNA Barcoding and sequencing (BRB-seq), which enables the preparation of hundreds of RNA samples for sequencing in a single tube. The BRB-seq technologies and kits enable researchers to discover novel biomarkers and essential data needed to develop new drugs at a fraction of the traditional cost and time.
FinSMEs
25/05/2022